Please assess the completion status of the following clinical trial:

Trial Title: The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* Age \> 18~* Histological diagnosis of non small-cell lung cancer (NSCLC)~* Stage IIIb or Stage IV disease (in IIIb, previous treatment with chemotherapy + radiotherapy, or metastatic supraclavicular lymph nodes or pleural effusion)~* Disease in progression~* Previous chemotherapy with platinum-derivative (and with \> 21 days from last administration)~Exclusion Criteria:~* ECOG performance status \> 2~* Age \> 75 years~* History of malignant neoplasm within the previous 5 years (except for baso- or spino-cellular skin carcinoma and in-situ carcinoma of the uterine cervix, provided they are being adequately treated)~* Previous treatment with docetaxel~* Presence of symptomatic cerebral metastasis~* Neutrophils \< 2.0 x 109/l, platelets \< 100,000/l, hemoglobin \> 10g/dl~* Bilirubin \< 1.5 x the upper normal limit~* SGOT , SGPT, or bilirubin \> 1.25 x the upper normal limits except in the presence of hepatic metastasis~* Creatinine \>1.25 x the upper normal limit~* Any concomitant pathology that would, in the Investigator's opinion, contraindicate the use of the drugs in the protocol~* Inability to comply with follow up~* Pregnant or nursing females

- Gender: ALL
- Minimum Age: None
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- docetaxel (Type: ACTIVE_COMPARATOR): single agent docetaxel
- docetaxel + vinorelbine OR gemcitabine (Type: EXPERIMENTAL): docetaxel in combination with either vinorelbine or with gemcitabine
- docetaxel + capecitabine (Type: EXPERIMENTAL): docetaxel in combination with capecitabine

Based on this trial design, predict the completion outcome and termination type (if applicable).